Skip to main content

Cookies on UKHSA data dashboard

We use some essential cookies to make this service work.

We'd like to set additional cookies so we can remember your settings, understand how people use the service and make improvements.

View cookies
UKHSA data dashboard

BetaThis is a new service - your feedback will help us to improve it.

Information
Correction to COVID-19 case rates data

Between 10 April and 27 April, published rolling-average case rates for COVID-19 were incorrect due to an error in population estimates used to calculate these metrics. As of 4pm on 28 April, these have been corrected. More information.

BackEntry title:

Hepatitis C percentage of people injecting drugs dependent on opioids who have received opioid agonist therapy

Last updated on Thursday, 10 April 2025 at 03:30pm

Summary

Topic
Hepatitis-C
Category
headline
API name
hepatitis-c_headline_PWIDUOpoidsROAT

Rationale

Measures to prevent transmission of hepatitis C virus are a cornerstone of the public health response to eliminate hepatitis C as a public health threat in England. Harm reduction interventions such as opioid agonist therapy (OAT) are important for people who inject drugs in order to prevent and reduce the risk of transmission of hepatitis C virus as well as reduce the risk of reinfection following treatment.

Definition

This metric shows the proportion of people who inject drugs who are dependent on opioids that have received OAT.

Methodology

This figure was calculated by comparing the most recent opiate use prevalence estimates from the Department of Health and Social Care (DHSC) and the UKHSA with prescribing data from DHSC’s National Drug Treatment Monitoring System.

Back to top